His main research concerns Positron emission tomography, Nuclear medicine, Radiology, Fluorodeoxyglucose and Pathology. His Positron emission tomography research is multidisciplinary, incorporating perspectives in Radiation treatment planning, Radiation therapy, Chemotherapy, Lymphoma and Lung cancer. Wolfgang A. Weber interconnects Pancreatic mass, Contrast medium and Pancreatic disease in the investigation of issues within Nuclear medicine.
His studies deal with areas such as Breast cancer and Prostate cancer as well as Radiology. His Fluorodeoxyglucose research includes themes of Preoperative care, Malignancy, Pancreatic cancer, Carcinoma and Glucose analog. The Pathology study combines topics in areas such as Fluoroethyl, Glioma and Biodistribution.
His primary areas of study are Nuclear medicine, Positron emission tomography, Prostate cancer, Radiology and Internal medicine. His study in Nuclear medicine is interdisciplinary in nature, drawing from both Lesion and Biodistribution. His Positron emission tomography course of study focuses on Pathology and Cancer.
His work deals with themes such as Radionuclide therapy and Urology, which intersect with Prostate cancer. His study in the field of Fdg pet ct also crosses realms of In patient. He usually deals with Internal medicine and limits it to topics linked to Oncology and Immunotherapy.
Nuclear medicine, Prostate cancer, Positron emission tomography, Internal medicine and Lesion are his primary areas of study. His research integrates issues of Radiation therapy and Biodistribution in his study of Nuclear medicine. Wolfgang A. Weber combines subjects such as Radiology and Cohort with his study of Prostate cancer.
As a part of the same scientific study, Wolfgang A. Weber usually deals with the Internal medicine, concentrating on Oncology and frequently concerns with Taxane, Enzalutamide, Anemia, Adverse effect and Toxicity. His Lesion study is concerned with Pathology in general. Wolfgang A. Weber has researched Pathology in several fields, including Molecular imaging and Cancer.
His primary scientific interests are in Prostate cancer, Nuclear medicine, Prostatectomy, Radiation therapy and Lymph node. His Prostate cancer research is multidisciplinary, relying on both Chemotherapy, Cohort and Urology. PET-CT and Pet imaging are the primary areas of interest in his Nuclear medicine study.
The study of Prostatectomy is intertwined with the study of Positron emission tomography in a number of ways. His research in Positron emission tomography intersects with topics in Histopathology, Magnetic resonance imaging, Dissection and Receiver operating characteristic. His Lymph node research incorporates themes from Biochemical recurrence and Breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard;Roberto Delgado-Bolton;Wim J. G. Oyen;Francesco Giammarile.
European Journal of Nuclear Medicine and Molecular Imaging (2015)
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E. Juweid;Sigrid Stroobants;Otto S. Hoekstra;Felix M. Mottaghy.
Journal of Clinical Oncology (2007)
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
Ronald Boellaard;Mike J. O'Doherty;Wolfgang A. Weber;Felix M. Mottaghy.
European Journal of Nuclear Medicine and Molecular Imaging (2010)
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
Derek W. Bartlett;Helen Su;Isabel J. Hildebrandt;Wolfgang A. Weber.
Proceedings of the National Academy of Sciences of the United States of America (2007)
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Florian Lordick;Katja Ott;Bernd-Joachim Krause;Wolfgang A Weber.
Lancet Oncology (2007)
Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
Wolfgang A. Weber;Katja Ott;Karen Becker;Hans-Joachim Dittler.
Journal of Clinical Oncology (2001)
Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography
Roland Haubner;Hans-Jürgen Wester;Wolfgang A. Weber;Christian Mang.
Cancer Research (2001)
Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations
N. Avril;C.A. Rosé;M. Schelling;J. Dose.
Journal of Clinical Oncology (2000)
Glycosylated RGD-Containing Peptides: Tracer for Tumor Targeting and Angiogenesis Imaging with Improved Biokinetics
Roland Haubner;Hans-Jürgen Wester;Fred Burkhart;Reingard Senekowitsch-Schmidtke.
The Journal of Nuclear Medicine (2001)
Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD
Roland Haubner;Wolfgang A Weber;Ambros J Beer;Eugenija Vabuliene.
PLOS Medicine (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: